Beware of the foam in the craze for weight-loss drugs! Analysts warn that Novo Nordisk's valuation is approaching skyrocketing prices
楚一帆
发表于 2023-10-19 13:21:17
280
0
0
The craze for weight-loss drugs is spreading in the US stock market. However, some analysts warn that the craze for weight-loss drugs in the stock market is creating a foam.
Novo Nordisk, the research and development company of weight loss drugs Ozempic and Wegovy, has seen a cumulative increase of about 50% in its stocks listed on the New York Stock Exchange within a year; Lilly, the company behind the drug Mounjaro, saw its stock price rise by 66.37% during the year.
Kepler Cheuvreux analyst David Evans is clearly wary of such stock price fluctuations. He pointed out that the valuation of weight loss drug companies is now too high.
Evans said that his team believes that the weight loss craze is just a foam, and there are no factors driving its continued growth in the near future.
Skyrocketing valuation
In early September, Novo Nordisk's stock price soared due to the popularity of weight loss drugs, replacing LVMH, the world's largest luxury goods company, as the largest company by market value in Europe, interrupting LVMH's two and a half year winning streak.
Goldman Sachs Group predicted this week that the market size of weight loss drugs will reach $100 billion by 2030. JPMorgan Chase emphasized that Lilly and Novo Nordisk are expected to continue dividing the market. These views undoubtedly strongly drove up the stock prices of Novo Nordisk and Lilly.
At the same time, Wal Mart once pointed out in the report that the price behind the bright prospect of weight loss drugs is the weakening of food demand. This report directly caused stock price fluctuations in many food companies, including Coca Cola, and became a laughing stock in Ozempic's spotlight.
However, Evans pointed out that a Novo Nordisk study in August found that Wegovy can effectively reduce the risk of heart disease and stroke, which drove the stock's rapid rise thereafter. But the trend of this stock price requires more proof, and Wegovy's peak sales need to double again to reach over $25 billion to justify its current valuation.
Evans added that Novo's valuation has become excessively high compared to its historical average and peer performance, and this day's valuation requires more performance growth to support.
Jefferies and Societe Generale's analysis also share the same sentiment, warning that Novo Nordisk's stock may face a 40% decline risk.
Last Friday, Novo Nordisk raised its annual sales and profit forecast for the third time, with an expected sales growth of between 32% and 38% this year, and an increase in pre interest and tax profit growth of between 40% and 46%.
The market is still waiting for further financial data, and Novo Nordisk will release its third quarter financial report on November 2nd.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- 20 dollars! Apple may charge for this feature! Analyst: Intended to pass on some costs to users
- Apple phones equipped with AI are about to be launched. Institutional analysts predict that the monthly fee for Apple Intelligence may be above $9.99
- Gold price breaks through $2500, hits new high again, Federal Reserve cuts interest rate as timing approaches
- High energy warning! Wall Street bears shout: US economic recession approaching, US stocks may plummet by 70%!
- The hottest 'Trump deal' of the year? Analyst: Bitcoin is expected to rise to $90000 by the end of the year!
- Analysts interpret ASML's' explosion ': global chip factory overcapacity but not industry apocalypse
- Tianfeng International analyst Guo Mingchi: Apple's affordable Vision Pro production has been postponed until after 2027
- Analysts dramatically raise S&P 500 target level: Bank of America waves 6666, Deutsche Bank shouts 7000 points
- Micron Technology's revenue outlook falls short of analysts' expectations, causing its stock price to plummet by approximately 18% after market hours
- Micron Technology's revenue outlook falls short of analysts' expectations, causing its stock price to plummet by approximately 18% after market hours
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
【ビットコインが飛び込む!32万人超の爆倉】データによると、過去24時間で世界には32万7000人以上の爆倉があり、爆倉の総額は10億ドルを超えた。
- 断翅小蝶腥
- 3 天前
- 支持
- 反对
- 回复
- 收藏